Integrative Obesity Care for Better Cardiometabolic Health

Find out how integrative obesity and cardiometabolic care can help you achieve sustainable health and vitality.

Abstract

Welcome to this educational post, crafted for adults in their 40s through 60s navigating the complex intersections of weight, metabolic health, sleep, joint function, mood, and hormonal transitions. I am Dr. Alexander (Alex) Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. Drawing from my chiropractic, advanced practice nursing, and functional medicine training, as well as my clinical experience in integrative and injury care, I present a comprehensive guide to midlife obesity and its cardiometabolic complications, emphasizing modern, evidence-based practices.

This post integrates current findings from leading researchers and large clinical trials, including foundational work by the American Heart Association on obesity and cardiovascular disease, the SELECT trial on semaglutide’s effect on major adverse cardiovascular events, STEP-HFpEF and SUMMIT data addressing obesity-related heart failure, SURMOUNT-1 and STEP 1 on diabetes prevention and weight loss, emerging guidance for MASLD/MASH (formerly NAFLD/NASH), and robust evidence on obstructive sleep apnea, osteoarthritis, and mental health. My purpose is to translate these insights into practical, patient-centered strategies.

At Injury Medical Clinic PA in El Paso, Texas—also known as Mission Plaza Injury Medical Clinic—our multidisciplinary, integrative team model pairs my roles in chiropractic, advanced practice nursing, and functional medicine with the medical oversight of our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD, a board-certified internist with over 40 years of experience (NPI #1164426749; Texas MD License #J2933). This collaborative framework reflects a modern integrative or injury clinic structure, where an MD partners with a chiropractor to unify medical direction with neuromusculoskeletal expertise, functional diagnostics, rehabilitation, and lifestyle medicine.

In this post, I explain:

• Why modest weight loss of 5 to 10 percent yields clinically significant benefits and how incremental targets of 10 to 15 percent and beyond transform health outcomes.
• How central adiposity and visceral fat ignite chronic inflammation, insulin resistance, hypertension, atherogenic dyslipidemia, MASLD/MASH, and sleep apnea.
• How integrative chiropractic care fits seamlessly into a comprehensive treatment plan by removing musculoskeletal barriers to movement, improving neuromuscular control and pain thresholds, and enabling sustainable physical activity.
• How to screen, stratify risk, and create unified care plans for cardiometabolic syndrome, heart failure risk (Stage A), dyslipidemia, hypertension, diabetes and prediabetes, MASLD/MASH, obstructive sleep apnea, osteoarthritis, depression and chronic stress, and sarcopenic obesity.
• Why menopause requires targeted body recomposition strategies—higher protein intake, resistance training, and carefully selected pharmacotherapies—to preserve muscle and bone, reduce visceral fat, and improve vasomotor symptoms.
• Two detailed case studies: “Robert,” a 55-year-old with diabetes, obesity, knee osteoarthritis, and sleep apnea; and a menopausal care journey highlighting “Maggie” and “Maria,” with insulin resistance, dyslipidemia, sarcopenic obesity, OA, and cardiovascular risk.

This post is designed to be easy to read and to take you on an understandable journey through the physiology, diagnostics, and therapeutics of midlife health. It reflects a unified voice from my clinical practice and collaborative care with Dr. Cardenas. Where appropriate, I include APA-7 style in-text citations and hyperlinked references.

Our Integrative Model and Philosophy of Care

I work at the intersection of chiropractic, advanced practice nursing, and functional medicine. My focus is on the body’s interconnected systems—especially how neuromusculoskeletal function intersects with metabolic health, sleep, and psychological well-being. Through Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, I share clinical responsibilities with Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Internal Medicine; NPI #1164426749; Texas MD License #J2933), a board-certified internist and mentor who provides medical oversight rooted in four decades of experience.

What Our Collaborative Care Looks Like

• Medical direction and internal medicine oversight: Dr. Cardenas supervises diagnostics, risk stratification, and prescription management for cardiometabolic conditions, liver disease, sleep apnea, and high-risk scenarios, ensuring evidence-based medical safety.
• Integrative chiropractic care: I use targeted spinal and extremity adjustments to restore joint function and alignment, myofascial therapies to reduce pain, and neuromotor retraining to improve movement efficiency and exercise tolerance.
• Functional medicine testing and analysis: Advanced labs for insulin resistance (fasting insulin, HOMA-IR), atherogenic dyslipidemia (ApoB, Lp(a)), and metabolic liver risk (FIB-4, fibrosis assessment) help us identify root causes and personalize therapy.
• Rehabilitation and physical therapy: We integrate corrective exercise, physical therapy, and careful loading progression to rebuild capacity while protecting injured or degenerative joints.
• Behavioral and lifestyle medicine: We address sleep architecture, stress management, habit coaching, and environmental factors that shape behavior, connecting patients to counseling when needed.

This multidisciplinary setup is common in integrative or injury care clinics and leverages the complementary strengths of chiropractic, internal medicine, functional diagnostics, and therapeutic exercise. Patients benefit from coordinated care, consistent messaging, and a plan calibrated to their lived realities, pain thresholds, and metabolic profiles.

Redefining Success in Obesity Treatment: Beyond the Scale, Toward Health Gains

Obesity treatment is not about the number on the scale—it’s about reducing adiposity, reversing health risks, and improving quality of life. The difference is crucial: we aim to reduce metabolically harmful fat (particularly visceral adipose tissue or VAT) while preserving or increasing lean mass.

What Success Looks Like

• Reduce adiposity, focus on visceral fat: Lower VAT to decrease systemic inflammation and insulin resistance.
• Preserve or increase muscle: Prevent sarcopenia through nutrition and resistance training to protect metabolic rate and functionality.
• Reverse risk factors: Improve glycemia, blood pressure, and lipid particle profiles; relieve liver inflammation; reduce sleep apnea burden.
• Restore quality of life: Improve energy, sleep, mobility, pain levels, and mental well-being.

The Power of Modest Weight Loss

• 5%: Early improvements in prediabetes and type 2 diabetes markers often begin here.
• 5%: Significant benefits in dyslipidemia, knee osteoarthritis pain, depression, and overall well-being.
• 10%: Meaningful changes in hypertension, MASLD resolution, and sleep apnea severity; often the threshold for medication de-escalation.
• 15% and beyond: Extensive cardiometabolic risk reduction, symptom relief, and improved functional capacity.

These thresholds are supported by clinical syntheses and trials showing graduated benefits with each increment of weight loss (Ryan & Yockey, 2017). My clinical observation mirrors this: patients feel better early, often before substantial weight change, as they decrease processed food intake, improve sleep, and begin gentle movement.

Cardiometabolic Syndrome: Understanding the Central Machine of Metabolic Risk

The cardiometabolic syndrome is a cluster of interlinked clinical problems—central obesity, insulin resistance, dyslipidemia, hypertension, and impaired glycemic control—that co-occur due to visceral fat biology and chronic inflammation. This syndrome is common in adults aged 40 to 60 and accelerates with a sedentary lifestyle and stress.

The Physiology of Visceral Fat and Insulin Resistance

• Visceral fat acts as an endocrine organ: It secretes pro-inflammatory cytokines (e.g., TNF-α, IL-6), disrupting insulin signaling and creating systemic insulin resistance (Powell-Wiley et al., 2021).
• Hyperinsulinemia and endothelial dysfunction: Elevated insulin and inflammation impair endothelial function, leading to vasoconstriction and hypertension.
• Free fatty acids overexpose liver and muscle: FFAs from dysfunctional adipocytes promote hepatic steatosis and block insulin signaling in skeletal muscle.

This rolling cascade leads to the familiar clinical pattern: rising blood pressure, increasing triglycerides, low HDL, elevated ApoB, a slow drift in fasting glucose and A1c, and expanding waist circumference.

Recognizing Cardiometabolic Syndrome

• Central obesity: Waist circumference greater than 40 inches (102 cm) in men and 35 inches (88 cm) in women is a key marker.
• Dyslipidemia pattern: High triglycerides, low HDL, and a predominance of small, dense LDL particles.
• Hypertension: Elevated blood pressure despite medication or lifestyle attempts.
• Dysglycemia: Elevated fasting glucose, impaired glucose tolerance, or elevated A1c.

We treat waist measurement as a vital sign—because clinically, it is. It predicts VAT burden, portal FFA delivery to the liver, and the subsequent risk of atherogenesis and fatty liver disease.

Our Risk Assessment Strategy

• Vital signs with a metabolic lens: Blood pressure, waist circumference, and resting heart rate with attention to autonomic balance.
• Body composition analysis: Bioimpedance and, when possible, DEXA to track fat and lean trends, particularly VAT and skeletal muscle.
• Advanced labs:

• • Fasting insulin, glucose, and HbA1c for IR and glycemic control.
  • ApoB and Lp(a) to quantify atherogenic particle number and genetic risk.
  • Traditional lipids: LDL-C, HDL-C, TG for trend tracking.

• Imaging when indicated:

• • Coronary artery calcium (CAC) scoring allows direct assessment of atherosclerotic burden.

• Psychosocial evaluation:

• • Stress load, depressive symptoms, support systems, and weight bias experiences—all influence adherence and outcomes.

This comprehensive intake informs our interventions and sets realistic, stepwise goals, reducing overwhelm and building momentum.

Obesity and Cardiovascular Disease: From Mechanistic Burden to Event Reduction

Obesity burdens the cardiovascular system via mechanical load, hemodynamic stress, endocrine inflammation, and metabolic dysregulation. Visceral fat around the heart is particularly concerning.

The Danger of Pericardial and Epicardial Fat

• Pericardial fat: Outside the pericardial sac.
• Epicardial fat: Inside the pericardial sac, sharing microcirculation with myocardium and coronaries.
• Why it matters: Epicardial fat secretes inflammatory mediators directly bathing the myocardium and coronary endothelium, promoting plaque formation, atrial fibrillation, and diastolic dysfunction (Powell-Wiley et al., 2021).

This is a direct example of fat mass disease—a structural and inflammatory phenomenon combined.

SELECT Trial: A Landmark for Cardiovascular Outcomes

The SELECT trial evaluated semaglutide in people with overweight or obesity and established cardiovascular disease without diabetes and demonstrated a 20 percent reduction in major adverse cardiovascular events (MACE), placing obesity pharmacotherapy alongside statins for event reduction (Lincoff et al., 2023). This trial shifted clinical paradigms: treating obesity itself reduces hard cardiovascular outcomes.

Heart Failure Risk and Early Intervention

Heart failure staging acknowledges Stage A (at-risk) patients—common in adults with obesity, hypertension, and diabetes. Obesity-driven hemodynamic load and epicardial fat contribute to HFpEF pathophysiology. In Stage A, our goals emphasize:

• Weight reduction of 10 to 15 percent
• Mediterranean or DASH eating patterns
• 150 minutes per week of moderate-intensity exercise, adapted to musculoskeletal realities
• Sleep optimization
• Pharmacotherapy where appropriate (GLP-1/GIP agonists)

STEP-HFpEF showed semaglutide improved HFpEF symptoms, function, and health status in patients with obesity (Kosiborod et al., 2023). SUMMIT data with tirzepatide suggest similar benefits. Treating obesity becomes a central strategy for this evolving heart failure phenotype.

Atherogenic Dyslipidemia: Treating Particle Number and Insulin Resistance

Obesity-linked insulin resistance creates a distinctive dyslipidemia: high triglycerides, low HDL, and small, dense LDL particles. LDL-C alone is insufficient for risk prediction; we should focus on particle number, assessed via ApoB (Grundy et al., 2019).

Why ApoB Matters

• Each atherogenic particle contains one ApoB molecule.
• Elevated ApoB reflects total particle burden (LDL, VLDL, IDL), which drives atherosclerosis.
• Insulin resistance increases particle number and a small, dense phenotype prone to retention in arterial walls.

Integrative Treatment

• Weight reduction of 5 to 15 percent reduces triglycerides, raises HDL, and lowers ApoB.
• Nutrition: High-fiber, Mediterranean-style eating; soluble fibers (oats, barley, legumes) aid LDL lowering; healthy fats support HDL.
• Exercise: 150 minutes per week of moderate aerobic activity; resistance training for muscle mass and insulin sensitivity.
• Pharmacotherapy: Statins to lower ApoB; GLP-1/GIP agents to reduce weight and improve lipid profiles.

Mechanistically, lowering insulin and FFA flux reduces hepatic VLDL production, remodels particle profile, and restores adipose tissue insulin sensitivity.

Hypertension in Obesity: Mechanisms and De-prescribing Through Weight Loss

Hypertension rises sharply with BMI. Obesity accounts for an estimated 78 percent of primary hypertension risk in men and 65 percent in women. Drivers include:

• RAAS activation from renal compression by visceral fat
• Endothelial dysfunction and vasoconstriction from inflammatory cytokines
• Increased cardiac output and blood volume

Weight Loss Effects

Modest reduction (3 to 9 percent) can decrease systolic and diastolic pressure by ~3 mmHg; 10 to 15 percent yields larger drops. Our protocol:

• DASH or Mediterranean-derived eating patterns
• Aerobic exercise and resistance training
• Home blood pressure monitoring with logs
• Titration and de-prescribing with medical oversight as weight loss progresses

With integrated care, many patients reduce antihypertensive doses, improving energy and cognition while supporting glycemic targets.

Insulin Resistance: The Central Engine of Metabolic Dysfunction

Insulin resistance precedes type 2 diabetes by 10 to 15 years. It manifests as fasting hyperinsulinemia long before glucose measures change. Chronic elevation of insulin:

• Promotes fat storage and inhibits lipolysis
• Increases hunger and reactive hypoglycemia
• Lowers basal metabolic rate over time

Lab Tools for Early Detection

• Fasting insulin: <5 µIU/mL is desirable; >8 to 10 µIU/mL suggests hyperinsulinemia
• HOMA-IR: A practical index; >1.8 to 2.0 indicates insulin resistance
• Triglyceride/HDL ratio: >3.0 suggests insulin resistance; <1.5 is ideal
• A1c trend: Rising within the normal range can be an early warning

Population data underscore the link between insulin resistance indices and cardiovascular mortality, particularly in adults under 65 (Wang et al., 2023). Early identification allows preemptive intervention.

Integrated Treatment Approach

• Targeted weight reduction: Even 5 to 10 percent improves insulin sensitivity.
• Lower-carbohydrate eating: Reduces insulin demand, breaks hyperinsulinemic cycles, and allows fat oxidation.
• Pharmacotherapy: Metformin and GLP-1/GIP agents (with medical oversight) complement lifestyle interventions.
• Chiropractic care to reduce pain and sympathetically driven stress: By improving neuromuscular function and downshifting autonomic tone, patients tolerate exercise better and decrease cortisol burden.

In my practice, addressing insulin resistance early shifts long-term trajectories—from progressive disease to remission potential.

Diabetes and Obesity: Treating the Root to Reverse the Course

Type 2 diabetes emerges when the beta-cell capacity cannot match the burden of insulin resistance. Treating weight and insulin dynamics often yields greater downstream benefits than focusing solely on glucose metrics.

Evidence for Weight-Centric Strategies

• Look AHEAD demonstrated that intensive lifestyle intervention produced sustained weight loss and reduced need for glucose, lipid, and blood pressure medications (Look AHEAD Research Group, 2014).
• 2 to 5 percent weight loss can reduce fasting glucose by around 20 mg/dL, nudging A1c toward normal ranges.

Modern Pharmacotherapy

• GLP-1 receptor agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) support glucose control and significant weight loss, improve satiety, and reduce cravings. They also address comorbidities like OSA and MASLD through weight-dependent effects.
• SURMOUNT-1 showed that tirzepatide reduced progression to diabetes by 94 percent in prediabetes and induced ~23 percent weight loss (Wharton et al., 2023).
• STEP 1 showed semaglutide produced ~15 percent weight loss and 84 percent reversion to normoglycemia in prediabetes (Wadden et al., 2021).

Our clinic uses these agents within an integrative framework, under Dr. Cardenas’ oversight, prioritizing safety, rational sequencing (e.g., tapering sulfonylureas), and careful titration to minimize adverse effects.

MASLD/MASH: The Liver’s Silent Burden in Metabolic Disease

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) replaces NAFLD, and MASH replaces NASH, clarifying the metabolic drivers of liver fat and inflammation (Rinella et al., 2023). More than two-thirds of patients with obesity have MASLD.

Disease Progression

MASLD → MASH → Fibrosis → Cirrhosis → Liver failure or hepatocellular carcinoma

Screening and Risk Stratification

• Liver enzymes: ALT > AST is common in MASH; regular monitoring every 2 to 3 years in at-risk patients.
• Incidental imaging: Review past radiology reports for “hepatic steatosis.”
• FIB-4 index: Uses age, AST, ALT, and platelets to triage fibrosis risk (low, indeterminate, high).
• FibroScan: Vibration-controlled elastography for liver stiffness, guiding further care.
• Rule out other causes: Viral hepatitis, autoimmune disease, hemochromatosis, alcohol, medications.

Treatment Strategy

• Weight loss ≥10 percent is the primary lever—resolves steatosis, reduces inflammation, and can reverse fibrosis.
• Nutrition: Mediterranean-style, lower-carbohydrate and lower-fat emphasis tailored to insulin resistance, with abundant fiber and minimal ultra-processed foods.
• Resistance and aerobic training: Improve insulin sensitivity and reduce hepatic fat.
• Pharmacologic options:

• • Vitamin E in select non-diabetic patients
  • GLP-1/GIP agonists for weight reduction and metabolic improvements
  • Resmetirom (FDA 2024) for MASH with F2-F3 fibrosis—managed with hepatology collaboration

In practice, we integrate dietary therapy, progressive movement, and targeted medication under internal medicine supervision to protect and restore liver health.

Chronic Stress, Depression, and Weight: The Mind-Body Feedback Loop

Chronic stress elevates cortisol, drives cravings for energy-dense foods, promotes visceral fat storage, and impairs self-regulation and sleep quality. Depression and obesity frequently co-occur, especially in women, and weight bias compounds distress and avoidance of care.

Our Compassionate, Integrated Approach

• Normalize a 5 to 10 percent initial weight-loss goal to build early wins.
• Sleep hygiene and OSA evaluation: Improve sleep architecture, reset hormonal signaling related to appetite and insulin sensitivity.
• Processed food reduction and glycemic stability: Stabilize mood and energy.
• Gentle movement: Leverage exercise as an antidepressant; chiropractic care helps reduce pain barriers to participation.
• Screening: PHQ-9, GAD-7, PSS to track and tailor interventions.
• Medication choices: Prefer weight-neutral or weight-negative antidepressants when pharmacotherapy is indicated.

Our therapeutic alliance emphasizes empathy and nonjudgment, actively mitigating the harm of weight stigma in clinical settings.

Musculoskeletal Pain and Mobility: Biomechanics Meet Metabolism

Mechanical load across joints multiplies with body weight—three times body weight when walking, six times on stairs, and up to ten times during running or jumping. Chronic overload plus systemic inflammation leads to osteoarthritis and functional decline.

Our Evaluation and Treatment

• Functional tests: “Get Up and Go,” chair-stand, grip strength, balance, and gait analysis.
• Imaging: X-rays and MRI where indicated.
• Chiropractic care:

• • Spinal and pelvic adjustments restore kinetic chain mechanics.
  • Extremity adjustments improve joint play and neuromuscular control.
  • Myofascial techniques reduce guarding and pain, lowering the threshold for movement.

• Weight reduction: Each pound lost reduces knee load by 3 to 4 pounds; a 10-pound loss can feel like 30 to 40 pounds of pressure relief.
• Physical therapy: Customized strengthening and mobility programs; progressive overload principle; emphasis on quadriceps/gluteal strength for knee stability.
• Non-weight-bearing exercise: Pool-based cardio and cycling for aerobic fitness without worsening joint pain.
• Pharmacotherapy: STEP 9 suggests semaglutide can reduce weight and knee OA pain—useful for dual benefits in select patients.

We aim to break the pain-inactivity-weight-gain cycle with coordinated mechanical correction, pain relief, and progressive conditioning.

Obstructive Sleep Apnea: The Sleep-Metabolism Crossroads

OSA risk rises sharply with obesity due to soft tissue fat in the upper airway, increased neck circumference, and decreased airway muscle tone. Repetitive apneas fragment sleep, increase sympathetic drive, elevate cortisol, impair insulin sensitivity, and worsen hunger signaling.

Screening and Diagnosis

• STOP-BANG questionnaire and Epworth Sleepiness Scale
• Polysomnography (PSG) or home sleep apnea testing where appropriate
• Apnea-Hypopnea Index (AHI) severity classification

Treatment and New Indications

• CPAP remains first-line for moderate to severe OSA.
• Weight reduction of 5 to 15 percent can markedly reduce AHI and, in mild OSA, may resolve the condition.
• Tirzepatide now carries an FDA indication (approved June 2024) for moderate-to-severe OSA in adults with obesity following SURMOUNT-OSA trial results (Malhotra et al., 2024).

• • Substantial AHI reduction observed in CPAP-naïve and CPAP users.
  • Mechanism: weight loss and reduced upper airway fat burden.

• Lifestyle: Avoid sedatives and alcohol at night; positional therapy adds incremental benefit.

By integrating metabolic care with sleep medicine, we address the bidirectional relationship between OSA and insulin resistance.

Evidence Snapshot: Major Trials Shaping Modern Care

• SELECT: Semaglutide reduced MACE in people with overweight/obesity and established CVD without diabetes (Lincoff et al., 2023).
• STEP-HFpEF: Semaglutide improved symptoms, function, and quality of life in obesity-related HFpEF (Kosiborod et al., 2023).
• SURMOUNT-OSA: Tirzepatide significantly reduced AHI in moderate-to-severe OSA with obesity; FDA indication approved in June 2024 (Malhotra et al., 2024).
• STEP 9: Semaglutide reduced weight and knee OA pain (Mosenzon et al., 2023).
• SURMOUNT-1: Tirzepatide induced ~23 percent weight loss and reduced progression from prediabetes to diabetes by 94 percent (Wharton et al., 2023).
• STEP 1: Semaglutide produced ~15 percent weight loss and 84 percent reversion to normoglycemia in prediabetes (Wadden et al., 2021).
• MASLD/MASH: Global consensus refined nomenclature to emphasize metabolic drivers (Rinella et al., 2023).
• Resmetirom: First FDA-approved agent (2024) for MASH with F2-F3 fibrosis—used with hepatology coordination.

These trials underpin our care models, inform shared decision-making, and demonstrate that treating obesity is disease modification.

Case Study: Robert’s Integrated Care Journey

“Robert” is a 55-year-old Mexican American male, married, working as a data analyst. He presented with knee pain limiting movement, daytime fatigue, and low libido. His history includes progressive weight gain over two decades, a sedentary lifestyle, and inconsistent CPAP use.

Initial Clinical Picture

• Diagnoses: Class III obesity, type 2 diabetes, hypertension, dyslipidemia, osteoarthritis, OSA.
• Measurements:

• • Weight: 275 lb; BMI: 40.6
  • Waist: 43 inches
  • BP: 148/92 mmHg on medication
  • A1c: 8.5 percent; Fasting glucose: 180 mg/dL
  • Triglycerides: 250 mg/dL; HDL: 35 mg/dL; LDL: 135 mg/dL
  • AST/ALT: 55/68 U/L (MASLD risk)
  • Testosterone: 250 ng/dL (low-normal)
  • STOP-BANG: 6 (high OSA risk); CPAP adherence: poor
  • PHQ-9: 10 (mild depression)
  • FIB-4: 2.1 (indeterminate risk; candidate for FibroScan)
  • Heart failure stage: Stage A (at risk)
  • Knee pain: 7/10

Stepwise Plan

• Medical optimization (Dr. Cardenas):

• • Discontinue glipizide to avoid weight gain and hypoglycemia.
  • Initiate tirzepatide with careful titration; continue metformin; reassess BP and lipid therapy as weight loss progresses.
  • Educate on sexual dysfunction etiology (microvascular factors) and anticipate improvement with metabolic control.

• Nutrition:

• • Reframe breakfast: Protein-forward to reduce late-day overeating and glycemic volatility.
  • Lower-carbohydrate focus; remove ultra-processed foods.
  • Workplace strategies: Prepare meals, control portions, and choose healthy snacks.

• Chiropractic and movement:

• • Relieve mechanical barriers: Spinal/pelvic and knee adjustments; soft tissue therapies to reduce pain and improve biomechanics.
  • PT referral: Quadriceps and hip strengthening, flexibility, and neuromotor control progression.
  • Non-weight-bearing cardio: Stationary bike and pool exercises initially.

• Sleep and behavior:

• • Refit CPAP mask; reinforce adherence.
  • Consider tirzepatide’s OSA indication and role in symptom improvement.
  • Frequent follow-ups for support, titration, and monitoring.

Outcomes Over Three Years

• Weight: 275 lb to 200 lb—a 75 lb loss (27.3 percent).
• BMI: 40.6 to 29.3.
• A1c: 8.7 percent to 5.4 percent (diabetes remission).
• Triglycerides: Significant improvement.
• Functional gains: Pain down, mobility up, energy restored.
• Sleep: Better CPAP adherence; decreased OSA severity.

The trajectory highlights consistency, tailored progression, and integrated care. Physiological remodeling takes months to years; sustained support is essential.

Menopause and Midlife Women’s Health: Weight, Body Composition, and VMS

Menopause typically occurs around age 51 and is characterized by declining estrogen. This hormonal shift increases visceral adiposity, induces anabolic resistance, reduces bone density, and elevates risk for cardiovascular disease, insulin resistance, and cognitive changes.

Weight Gain and Body Composition

• Increased central adiposity: Transition from gynoid to android pattern; rises in VAT drive insulin resistance and inflammation.
• Muscle and bone: Sarcopenia and osteopenia/osteoporosis risk escalate.
• Hormonal and behavioral drivers:

• • Increased ghrelin and decreased satiety signals
  • Lower MVPA levels
  • Insulin resistance and anabolic resistance to protein

• VMS: Often precede weight gain; reciprocal relationship where higher BMI/waist increase VMS frequency and severity; weight loss reduces VMS.

Integrated Menopause Care Goals

• Prevent further weight gain and reduce adiposity.
• Improve body composition: Prioritize muscle preservation and growth.
• Enhance mental well-being and sleep quality.
• Lower long-term disease risk (CVD, diabetes, osteoporosis).
• Improve quality of life and functional independence.

Foundational Interventions

• Protein optimization:

• • Target 1.2 to 1.6 g/kg ideal body weight per day; distribute 25 to 35 g protein per meal every 3 to 4 hours.
  • Emphasize animal proteins for leucine content; supplement with leucine-rich whey protein and vitamin D when needed (Bauer et al., 2013; Halfon et al., 2015).

• Resistance training:

• • Non-negotiable for sarcopenia prevention and bone health; 2 or more sessions per week focusing on progressive overload.

• Aerobic conditioning:

• • 150 to 300 minutes per week, scaled to tolerance.

• Chiropractic care:

• • Improve joint function, reduce pain, optimize posture and movement mechanics to enable consistent activity.

• Sleep and stress management:

• • Reduce cortisol-mediated belly fat gains; improve appetite signaling.

• Pharmacotherapy:

• • Review medications for weight effects.
  • Metformin for insulin resistance (off-label for prediabetes prevention).
  • GLP-1/GIP agonists for qualified cases.
  • Menopausal hormone therapy when appropriate; consider metabolic benefits on insulin sensitivity (Salpeter et al., 2006).
  • Non-hormonal VMS options when indicated.

These pillars create sustainable pathways through the menopausal transition, emphasizing body recomposition and symptom relief.

Sarcopenic Obesity: The Hidden Epidemic

Sarcopenic obesity is the coexistence of reduced muscle mass and increased fat mass, leading to decreased functional capacity and worsened metabolic risk. Inflammation from adipose tissue accelerates muscle catabolism, while decreased muscle mass lowers resting metabolic rate—fueling a vicious cycle.

Prevalence and Risk

• Overall adult prevalence: ~16 percent
• Ages 20 to 60: ~8 percent
• Over 60: >28 percent
• High prevalence in specific demographics: Among Mexican American women over 60, prevalence can exceed 60 percent (Du et al., 2019).
• Higher in metabolic disease:

• • Prediabetes: ~20 percent
  • Type 2 diabetes: ~35 percent
  • MASLD: ~25 percent
  • Post-bariatric surgery: ~22 percent (Pardo et al., 2021)

Identification

• Functional tests: Grip strength, chair-stand, gait speed, balance.
• Body composition: DEXA preferred for precise lean and fat delineation; BIA is a useful proxy when DEXA is unavailable.
• Clinical clues: Persistent fatigue, subjective heaviness and stiffness, and difficulty with daily tasks.

Treatment Strategy

• Nutrition:

• • Protein at 1.0 to 1.5 g/kg ideal body weight daily (Bauer et al., 2013).
  • Leucine-rich sources, evenly distributed.
  • Minimize ultra-processed carbohydrates to reduce inflammation and support insulin sensitivity.

• Exercise:

• • Cardiovascular: Build toward guideline levels, emphasizing consistency.
  • Resistance training: Anchor therapy—structured, progressive, and supervised when possible.

• Physical therapy:

• • Formal PT referrals using ICD-10 codes for sarcopenia (M62.84) and deconditioning (Z74.01).

• Chiropractic care:

• • Correct biomechanical issues, reduce pain, and restore confidence in movement.

By pairing metabolic and mechanical interventions, we reverse functional decline and reduce cardiometabolic risk.

Case Study: Maggie’s Perimenopausal Transition

“Maggie” is a 53-year-old CPA and law firm partner. She is managing career demands, raising teens, and caring for an aging parent—classic “sandwich generation” stressors. She experienced increasing vasomotor symptoms (VMS), insomnia, anxiety, and gradual weight gain beginning around age 50.

Clinical Trajectory

• Weight: 135 to 155 lb over three years; BMI: 22.6 to 27.5
• Waist circumference: 32 to 36.5 inches
• Fasting glucose: 92 to 104 mg/dL
• A1c: 5.3 to 5.8 percent (prediabetes)
• Fasting insulin: 11.7 µIU/mL (elevated)
• LDL-C: 98 to 128 mg/dL; Triglycerides: 110 to 155 mg/dL; HDL-C: 65 to 52 mg/dL
• Gabapentin 300 mg twice daily for hot flashes and insomnia
• Nightly wine use

Diagnosis

• Overweight/early obesity with central adiposity
• Prediabetes/insulin resistance
• Dyslipidemia with worsening trends
• Perimenopausal symptoms and high stress load

Plan

• Nutrition:

• • 90 to 100 g protein daily; distribute evenly across meals.
  • Net carbohydrates 50 to 100 g/day from vegetables and fruits.
  • Reduce nightly alcohol to improve sleep and insulin sensitivity; plan reduction collaboratively.

• Physical activity:

• • Increase cardio intensity separate from dog walks.
  • Introduce resistance training once weekly initially, then progress.

• Medical management:

• • Initiate metformin ER 500 mg daily (off-label for prediabetes prevention; Diabetes Prevention Program).
  • Reevaluate gabapentin efficacy; consider tapering if not effective.
  • Discuss candidacy for MHT for VMS and metabolic benefits.
  • Improve sleep hygiene and consider CBT-I if needed.

• Reassessment in three months:

• • If progress is insufficient, consider anti-obesity medications.

This approach addresses insulin resistance, central adiposity, and symptom burden, aiming for measurable improvements in waist, HOMA-IR, and fasting lipids.

Case Study: Maria’s Complex, High-Risk Profile

“Maria” is a 59-year-old health executive and nonprofit board member with multiple comorbidities:

• Prior myocardial infarction (3 years prior)
• Type 2 diabetes (10 years)
• Hypertension
• Dyslipidemia (elevated triglycerides)
• MASLD
• Severe bilateral knee osteoarthritis
• Class II obesity

Baseline

• BMI: 35.7
• A1c: 7.4 percent
• Triglycerides: 256 mg/dL; HDL-C: 37 mg/dL
• Elevated ALT/AST consistent with MASLD
• On metformin and insulin; not on a GLP-1 agonist
• DEXA:

• • Body fat: 57.8 percent
  • Lean muscle mass: 4th percentile
  • VAT: 3.4 liters
  • Waist: 43.5 inches

Diagnosis

• Class II obesity with sarcopenic obesity
• Uncontrolled type 2 diabetes with high atherogenic risk
• MASLD
• Severe knee osteoarthritis
• High cardiovascular risk following MI

Integrated Plan

• Nutrition:

• • Low-carbohydrate, high-protein framework to reduce insulin and TG.

• Team-based referrals:

• • Physical therapy for knee stabilization, global conditioning, and safe strength training.
  • Orthopedic surgery consult for injections and potential arthroplasty; advocate to counter bias and ensure full consideration of options.

• Medication optimization (Dr. Cardenas):

• • Initiate semaglutide for dual indications: diabetes/weight and MACE reduction in those with CVD history (Marso et al., 2016).
  • Gradually taper exogenous insulin as glycemic control and weight improve to remove pharmacologic weight gain drivers.

• Physical activity:

• • Daily non-weight-bearing cardio (swimming, water aerobics, or stationary bike).
  • Progressive resistance training with PT oversight.

This plan addresses her high cardiovascular risk while targeting sarcopenic obesity, liver health, and knee pain. Our explicit advocacy counters the systemic biases often faced by older women with obesity in accessing advanced orthopedic care.

How Integrative Chiropractic Care Fits In

Chiropractic care is a crucial enabler in our model. It bridges pain and movement—essential in a program that relies on physical activity to produce metabolic change.

What I Do as a Chiropractor in This Model

• Align and mobilize the spine and pelvis: Improve postural integrity and load distribution throughout the lower extremities.
• Address extremity joints: Gentle, specific adjustments to knees, hips, ankles, shoulders, and feet to restore joint play and reduce pain.
• Soft tissue therapies: Myofascial release and trigger point work to reduce muscle guarding and enhance flexibility.
• Neuromotor training: Reinforce stable, efficient movement patterns to conserve energy and protect joints.
• Pain modulation: Reduce nociceptive input and sympathetic activation, enhancing readiness for exercise and lowering stress.
• Clinical coaching: Set realistic movement goals aligned with patient context and create consistency plans that survive daily life pressures.

This care reduces barriers to exercise by alleviating pain and improving movement capacity—pivotal for maintaining weight loss, muscle mass, and cardiometabolic health.

Practical Protocols: How We Build and Sequence Care

We use a stepwise, patient-centered approach:

• Baseline Assessment:

• • Waist circumference, body composition, strength tests.
  • Labs: A1c, fasting glucose, fasting insulin (HOMA-IR), ApoB, Lp(a), liver enzymes, lipid panel.
  • Sleep and stress screening: STOP-BANG, Epworth, PHQ-9, GAD-7, PSS.
  • Medical history and medication review with attention to weight and metabolic effects.

• Priority Targets:

• • First 12 weeks: Reduce ultra-processed foods, establish protein distribution, begin low-impact cardio, introduce 1 to 2 resistance sessions/week, and optimize sleep.
  • Pain management: Chiropractic and PT to open the movement window.
  • Medical therapy: Titrate GLP-1/GIP agents where indicated; adjust or de-prescribe as metrics improve.

• Monitoring:

• • Every 2 to 4 weeks initially: Reinforce gains, titrate medications, troubleshoot barriers, and celebrate milestones.
  • Quarterly labs: Track A1c, fasting insulin, ApoB, TG/HDL updates.
  • Re-scan body composition at 3 to 6 months to track fat-mass and lean-mass changes.

• Long-Term Maintenance:

• • Shift from caloric restriction to maintenance energy levels.
  • Lock in resistance training and protein distribution to preserve lean mass.
  • Continue sleep and stress management to prevent drift into hyperinsulinemia.
  • De-prescribe when safe; always coordinate with internal medicine.

This sequence leverages early wins, prevents muscle loss, and supports sustained behavior change.

Clinical Observations from My Practice

Across my years treating personal injuries, metabolic disorders, and complex cases at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) and through my professional development work (see my practice and professional pages at dralexjimenez.com and LinkedIn), I consistently observe:

• Patients improve quickly when pain is controlled, and movement becomes feasible. Even small walks or short bouts of cycling start momentum.
• Removing ultra-processed foods yields early cognitive and energy gains, independent of weight.
• Distributed protein intake stabilizes satiety and improves adherence. Protein-first breakfasts are particularly impactful.
• Sleep is the great multiplier. CPAP adherence and sleep hygiene amplify metabolic and psychological benefits from other interventions.
• Muscle is medicine. Resistance training is the strongest predictor of long-term maintenance and functional independence.
• Empathy outperforms admonition. Addressing weight bias and listening deeply improves trust and adherence.
• Small increments add up. A 5 to 10 percent early weight loss is enough to reopen physiological flexibility and improve A1c, BP, TG, and liver enzymes.

These insights inform our whole-person approach, blending evidence-based medicine with hands-on care and pragmatic coaching.

Putting It All Together: A Patient-Centered Roadmap

• Start with clarity: Measure what matters—waist, composition, insulin, ApoB, sleep risk, mood.
• Reduce pain barriers: Chiropractic and PT make activity possible and safe.
• Reconstruct daily patterns: Protein timing, glycemic stability, and movement routines.
• Choose pharmacotherapy wisely: Use GLP-1/GIP agents where indicated, taper weight-promoting meds.
• De-prescribe when possible: As weight and metrics improve, reduce antihypertensives, insulin, and sedating agents with medical oversight.
• Protect sleep: Treat OSA, improve sleep hygiene, and align circadian cues.
• Respect menopause physiology: Increase protein, prioritize resistance training, consider MHT or non-hormonal options, and emphasize recomposition over weight alone.
• Sustainability over speed: Build habits around what patients can do consistently; celebrate and stack wins.

This roadmap honors the complexity of midlife health while keeping actions practical and achievable.

Conclusion: Treating Obesity Is Treating Disease

The past decade’s research confirms what many of us in integrative practice have observed: treating obesity modifies disease trajectories. We now have outcome-level evidence that targeted weight loss reduces cardiovascular events, improves heart failure symptoms, prevents diabetes progression, reduces OSA severity, alleviates osteoarthritis pain, and reverses liver inflammation.

At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic), our integrated model—combining chiropractic care, functional medicine diagnostics, rehabilitation, and internal medicine oversight by Dr. Maria Guadalupe Cardenas, MD—makes translating evidence into practice seamless. We connect metabolic science to musculoskeletal realities and patient lives, one measurable gain at a time.

If you are navigating midlife and struggling with weight, energy, sleep, pain, or menopausal symptoms, know this: a coordinated, compassionate, evidence-based path exists. And you do not have to walk it alone.

References

• Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015). Pharmacological management of obesity: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(2), 342–362.
• Bauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., Phillips, S., Sieber, C., Stehle, P., Teta, D., Visvanathan, R., Vellas, B., & Wolfe, R. (2013). Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE Study Group. Journal of the American Medical Directors Association, 14(8), 542–559.
• Diabetes Prevention Program Research Group. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine, 346(6), 393–403.
• Du, Y., Wang, X., Xie, H., Zheng, S., & Wu, X. (2019). Sarcopenic obesity: A new category of obesity in older adults. BMC Geriatrics, 19(1), 259.
• Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine, 385(6), 503–515.
• Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., … & Yancy, C. W. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082–e1143.
• Halfon, M., Phan, O., & Teta, D. (2015). Vitamin D: A review on its effects on muscle health, the risk of falls and fractures. Swiss Medical Weekly, 145, w14124.
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216.
• Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., … & STEP-HFpEF Trial Committees and Investigators. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. The New England Journal of Medicine, 389(12), 1069–1084.
• Le, T., & Chalmers, J. (2023). Menopause and weight gain. In StatPearls. StatPearls Publishing.
• Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., … & SELECT Trial Investigators. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232.
• Look AHEAD Research Group. (2014). Eight-year weight losses with an intensive lifestyle intervention: The Look AHEAD study. Obesity (Silver Spring, Md.), 22(1), 5–13.
• Lovejoy, J. C., Champagne, C. M., de Jonge, L., Xie, H., & Smith, S. R. (2008). Increased visceral fat and decreased energy expenditure during the menopausal transition. International Journal of Obesity, 32(6), 949–958.
• Malhotra, A., Grunstein, R. R., Fietze, I., et al. for the SURMOUNT-OSA Study Group. (2024). Tirzepatide for the treatment of obstructive sleep apnea and obesity. The New England Journal of Medicine.
• Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Saugstrup, S., Vilsbøll, T., & Warren, M. L. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine, 375(19), 1834–1844.
• Mosenzon, O., Blicher, T. M., Rosenlund, S., et al. (2023). Semaglutide 2.4 mg for the treatment of knee osteoarthritis in people with overweight or obesity: The STEP 9 randomized clinical trial [Conference presentation]. European Congress on Obesity (ECO) 2023.
• Pardo, C. F., Geloneze, B., Pareja, J. C., & de Souza, G. C. (2021). Sarcopenic obesity after bariatric surgery: A sleeping giant. Obesity Surgery, 31(7), 3274–3283.
• Phelan, S. M., Burgess, D. J., Yeazel, M. W., Hellerstedt, W. L., Griffin, J. M., & van Ryn, M. (2015). Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obesity Reviews, 16(4), 319–326.
• Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018). The Physical Activity Guidelines for Americans. JAMA, 320(19), 2020–2028.
• Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J. P., Gordon-Larsen, P., Lavie, C. J., … & American Heart Association Councils and Stroke Council. (2021). Obesity and cardiovascular disease: A scientific statement from the American Heart Association. Circulation, 143(21), e984–e1010.
• Rinella, M. E., Lazarus, J. V., Ratziu, V., et al. (2023). A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 78(6), 1966–1986.
• Ryan, D. H., & Yockey, S. R. (2017). Weight loss and improvement in comorbidities: Differences at 5%, 10%, 15%, and over. Current Obesity Reports, 6(2), 187–194.
• Salpeter, S. R., Walsh, J. M., Ormiston, T. M., Greyber, E., Buckley, N. S., & Salpeter, E. E. (2006). Meta-analysis: Effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes, Obesity and Metabolism, 8(5), 538–554.
• Schoenfeld, B. J., & Aragon, A. A. (2018). How much protein can the body use in a single meal for muscle-building? Implications for daily protein distribution. Journal of the International Society of Sports Nutrition, 15(1), 10.
• Wadden, T. A., Bailey, T. S., Billings, L. K., et al. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA, 325(14), 1403–1413.
• Wang, Z., Wang, J., Li, J., et al. (2023). Different insulin resistance indices and the risk of all-cause and cardiovascular mortality in a general U.S. population: A cohort study from 2001 to 2018. Cardiovascular Diabetology, 22(1), 19.
• Wharton, S., Blevins, T., Connery, L., et al. (2023). Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT-1 study. Obesity (Silver Spring, Md.), 31(1), 96–108.

SEO Tags: integrative chiropractic care, obesity medicine, midlife health, cardiometabolic syndrome, insulin resistance, GLP-1 semaglutide, tirzepatide, SELECT trial, STEP HFpEF, SURMOUNT OSA, STEP 1, SURMOUNT-1, MASLD MASH, resmetirom, atherogenic dyslipidemia, ApoB, hypertension, osteoarthritis, sleep apnea, menopause, sarcopenic obesity, resistance training, protein distribution, DEXA body composition, functional medicine, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, El Paso Texas